

# Review of: "Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia"

Joanna Zawitkowska

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

In this manuscript, the authors report a case of a 28-year-old male who was normolipidemic at baseline and developed severe hypertriglyceridemia and genetic variants, which could suggest a predisposition to this drug-induced metabolic condition. In my opinion, the manuscript is interesting, but require minor revision.

1. I suggest to present laboratory data in the table.

2. What about doses of PEG-ASP in this protocol? I understand that the protocol includes 4 doses of PEG- ASP in the induction phase and four doses in consolidation, yes?. I suggest to describe therapy more clearly.

In children with ALL and hypertriglyceridaemia without acute pancreatitis, there is no contraindication to the use of PEG-ASP as the role of this drug in the treatment of ALL is crucial. PEG-ASP was no longer administered to the patient - why. Please explain.